Madeleine Hull
Fen-phen was a combination of two appetite-suppressing drugs: fenfluramine and phentermine. Marketed as a miracle weight-loss pill, it gained rapid popularity in the 1990s, despite lacking FDA approval for the drugs' combination. However, fen-phen was soon linked to severe side effects, including valvular heart disease and pulmonary hypertension, resulting in its withdrawal from the market in 1997 and a wave of lawsuits against its manufacturer, Wyeth.
| Characteristics | Values |
|---|---|
| Brand name | Fen-Phen |
| Generic name | Fenfluramine/phentermine |
| Drug type | Appetite suppressant |
| Drug class | Anorectic |
| Administration | Oral |
| Availability | No longer widely available |
| Side effects | Fast heart rate, high blood pressure, trouble sleeping, dizziness, restlessness, valvular heart disease, pulmonary hypertension |
Explore related products
What You'll Learn
Fen-phen is a combination of fenfluramine and phentermine
Fen-phen is the popular name given to the combination of fenfluramine and phentermine. It is an anti-obesity medication that was sold in the early 1990s. Fen-phen was also used to treat severe obesity and fight some drug and alcohol addictions. The drug combination utilized two anorectics, with fenfluramine marketed as Pondimin and phentermine as an appetite suppressant.
Fen-phen was first introduced in 1992 by a research team led by Dr. Michael Weintraub of the University of Rochester. They claimed that the combination of fenfluramine and phentermine was more effective in treating obesity without causing the side effects of previous diet drugs. Despite not being approved by the FDA, this combination of weight-loss drugs received a lot of media attention and quickly became known as the miracle medicine "Fen-Phen".
However, in 1996, a 30-year-old woman developed heart problems after a month of using fen-phen, and subsequently died in February 1997. This prompted the Mayo Clinic to publish a paper in the New England Journal of Medicine discussing clinical findings in 24 people who had taken fen-phen. The FDA then received over a hundred additional reports of valvular heart disease in people taking fen-phen, fenfluramine alone, or dexfenfluramine alone. In 1997, the FDA ordered Wyeth to remove fenfluramine (Pondimin) and dexfenfluramine (Redux) from the market, acknowledging the extremely dangerous side effects of these drugs.
Today, fen-phen is no longer widely available. In 2005, American Lawyer magazine reported that more than 50,000 product liability lawsuits had been filed by alleged fen-phen victims, with total liability estimated to be as high as $14 billion.
Slow Carb Diet: No Dairy, Faster Results
You may want to see also
Explore related products
Fen-phen was a popular weight-loss treatment
The popularity of fen-phen as a weight-loss treatment was such that it was deemed a "miracle medicine". However, this perception changed when concerns arose about its side effects. In 1994, there were worries that fenfluramine could cause pulmonary hypertension, a rare but often fatal lung disease. Despite this, Wyeth, the manufacturer of fenfluramine, introduced dexfenfluramine (Redux), a chemical derivative of fenfluramine, in 1995, which was thought to carry fewer side effects.
Unfortunately, it was later discovered that Redux, when used with phentermine, caused the same heart problems as fen-phen. In 1997, the FDA ordered Wyeth to remove both Pondimin (fenfluramine) and Redux (dexfenfluramine) from the market due to their link to severe heart and lung damage, including valvular heart disease and primary pulmonary hypertension. This led to a wave of fen-phen litigation, with more than 50,000 product liability lawsuits filed by alleged victims, resulting in liability estimates as high as $14 billion.
While fen-phen is no longer widely available, the search for effective weight-loss treatments continues. The story of fen-phen highlights the importance of thoroughly researching potential side effects before taking any medication, especially those intended for weight loss, as the consequences can be life-threatening.
Empty Calories: How Much is Too Much?
You may want to see also
Explore related products
Fen-phen was linked to severe heart and lung damage
Fen-phen, a weight-loss drug combination used in the 1990s, was removed from the market after being linked to severe heart and lung damage. The drug combination of fenfluramine and phentermine, known as fen-phen, was shown to cause potentially fatal pulmonary hypertension and heart valve problems.
A French study in 1996 found that using fenfluramine increased a person's risk of pulmonary hypertension. This risk was higher for people taking the drug for more than three months. The most incriminating evidence came in 1997 when a Mayo Clinic doctor published a study in the New England Journal of Medicine. The research documented the health problems of 24 women taking fen-phen. None of these women had a history of heart disease, but after a year of taking the diet pill, eight developed pulmonary hypertension for the first time, and all of them showed significant heart valve damage. At least five required heart surgery.
In 1994, concerns were raised about fenfluramine's labelling, which listed only four cases of pulmonary hypertension when 41 had been observed. However, no action was taken until 1996. In 1995, the company introduced dexfenfluramine, which was hoped to cause fewer adverse effects. However, the medical officer of the Food and Drug Administration (FDA) insisted upon a black box warning of pulmonary hypertension risks. After he refused to approve the drug, the FDA management had a senior drug evaluator sign it off without the warning.
The problem with fen-phen comes from the very action that helps people lose weight. Fenfluramine increases serotonin levels in the brain, suppressing appetite. However, this mechanism can lead to harmful side effects, including pulmonary hypertension and heart valve damage. When a drug leads to the development of pulmonary hypertension, it is known as drug-induced pulmonary arterial hypertension (PAH). Excess serotonin forces blood vessels to contract, damaging the ones in the lungs.
Cooking Tofu for the HCG Diet: A Beginner's Guide
You may want to see also
Explore related products
Fen-phen was never approved by the FDA for weight loss
Fen-phen, a combination of fenfluramine and phentermine, was a popular weight-loss drug in the 1990s. Despite its popularity, the drug was never approved by the FDA for weight loss. In fact, it was linked to serious side effects, including heart valve damage and pulmonary hypertension, which could be potentially fatal.
The story of fen-phen's rise and fall is a cautionary tale in the world of weight-loss drugs. In the early 1990s, fen-phen was touted as a "`miracle medicine'" for weight loss. This was due to a research claim made in 1992 by Dr. Michael Weintraub of the University of Rochester, who asserted that the combination of fenfluramine and phentermine was more effective in treating obesity without the annoying side effects of previous diet drugs. The media quickly picked up on this story, and fen-phen became widely known as an easy way to lose weight.
However, despite the drug's popularity and the rising demand from patients, the FDA never approved fen-phen for safe use. This was because of concerns about its side effects. In 1994, a Wyeth official, Fred Wilson, expressed worries about fenfluramine's labelling, which mentioned only four cases of pulmonary hypertension when 41 had been observed. Unfortunately, no action was taken until 1996, and the drug continued to be available to consumers.
The consequences of fen-phen's unchecked side effects were dire. In 1997, two separate studies in the New England Journal of Medicine (NEJM) linked fen-phen to severe cardiac problems. Approximately one in three people exposed to fen-phen showed signs of abnormal heart issues. This prompted the FDA to pull the drug from the shelves that same year. The fallout from this debacle was significant, with more than 50,000 product liability lawsuits filed by alleged fen-phen victims and total liability estimated to be as high as $14 billion.
In conclusion, the case of fen-phen illustrates the importance of thorough testing and approval by regulatory bodies like the FDA before drugs are made available to the public. While weight loss may be a challenging endeavour, prioritising safety and efficacy in drug development is crucial to prevent harmful consequences.
Dr. Kellyann's Bone Broth Diet: 21 Days to Weight Loss
You may want to see also
Explore related products
Fen-phen was the subject of thousands of lawsuits
Fen-phen, a combination of fenfluramine and phentermine, was an anti-obesity medication sold in the early 1990s. It was marketed by American Home Products (later known as Wyeth) as Pondimin. The drug was found to cause potentially fatal pulmonary hypertension and heart valve problems, leading to its withdrawal from the market in 1997. This prompted a wave of lawsuits, with more than 50,000 product liability lawsuits filed by alleged fen-phen victims.
The drug combination utilised two anorectics, with fenfluramine acting as a serotonin-releasing agent and phentermine as a norepinephrine-releasing agent. While phentermine had side effects such as a fast heart rate, high blood pressure, and trouble sleeping, fenfluramine was the more concerning of the two. This was because it only temporarily reduced weight and, more alarmingly, caused valvular heart disease and pulmonary hypertension.
In 1996, a 30-year-old woman developed heart problems after using fen-phen for a month. Her death in February 1997 led to a front-page article in the Boston Herald. This tragedy brought renewed attention to the drug's dangerous side effects, with the Mayo Clinic publishing a paper in the New England Journal of Medicine discussing clinical findings in 24 people who had taken fen-phen. The FDA received additional reports of valvular heart disease in users of fen-phen and fenfluramine, prompting their request for the drug's withdrawal from the market in September 1997.
The litigation surrounding fen-phen resulted in significant financial consequences for Wyeth. The company initially offered settlements ranging from $5,000 to $200,000 to those who had sued, but thousands of injured persons rejected these offers as insufficient to cover their medical expenses. In total, Wyeth set aside $21.1 billion to cover the cost of the lawsuits, with the total liability estimated to be as high as $14 billion.
Fixing Your Diet in 21 Days: Crash or Keep?
You may want to see also
Frequently asked questions
Fen-phen is the popular name given to the combination of appetite suppressants fenfluramine and phentermine.
Fen-phen was used to treat patients with severe obesity problems and has even been used as a way to fight some drug and alcohol addictions.
Fen-fen was linked to severe heart and lung damage, including valvular heart disease and primary pulmonary hypertension.
Fen-phen is no longer widely available. It was removed from the market in 1997 after the FDA linked it to severe heart and lung damage.
